Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.

about

IL-20 bone diseases involvement and therapeutic target potential.The Biological Enhancement of Spinal Fusion for Spinal Degenerative Disease Cell-based RNAi screening and high-content analysis in primary calvarian osteoblasts applied to identification of osteoblast differentiation regulators

P2860

Q55121772-AF21F13B-850D-4CE3-B4EE-44398BD72746 Q57168746-436318BF-A0E6-4E6C-A0BB-B5579810B33E Q58719766-E1DE727F-4273-417B-A481-EA24020FD418

P2860

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.

Item

http://www.wikidata.org/entity/Q42364116

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.

@en

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.

@nl

type

Item

label

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.

@en

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.

@nl

prefLabel

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.

@en

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.

@nl

P1476

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.

@en

P2093

Michael R McClung

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.

Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys.

Preventing painful age-related bone fractures: Anti-sclerostin therapy builds cortical bone and increases the proliferation of osteogenic cells in the periosteum of the geriatric mouse femur.

Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

Geographic and ethnic disparities in osteoporotic fractures.

Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys.

P304

263-270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1759720X17726744

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28974988

http://www.w3.org/2001/XMLSchema#string

P921

osteoporosis

P932

5613857

http://www.w3.org/2001/XMLSchema#string

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.

about

P2860

P2860

Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932